The Priority Review

The stream · Daily digest

The stream: Sunday, November 1, 2026

1 brief, grouped by desk. Each is two sentences from one primary source, linked to it.

Machine-summarized from primary sources; not independently reported. How we use automation

Clinical trials · 1

  1. Abbott reports strong 30-day outcomes in TECTONIC IVL study

    The TECTONIC CAD IVL IDE Study enrolled 335 patients and met its primary safety endpoint with a 30-day target lesion failure rate of 0.3%. The study also achieved a primary effectiveness endpoint with procedural success in 97% of patients.

    Source: Company press release (PR Newswire), November 1, 2026